Current Edition

Amgen

For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and …

Continue Reading →
checkpoint inhibitors

Merck, Eisai’s 007 goes down as Keytruda-Lenvima combo fails in newly diagnosed lung cancer

Merck & Co. isn’t resting on Keytruda’s laurels. But an attempt to improve on the undoubtful cancer immunotherapy king with another agent has failed in …

Continue Reading →
biologics

Merck’s Hilleman Laboratories tees up $58M investment at new Singapore vaccine hub

Singapore has attracted a slate of vaccine heavyweights in recent years. Now, a Merck joint venture is getting in on the action, following in the …

Continue Reading →
divestment

Novartis may have a buyer for $21B generics unit Sandoz

Amid the industrywide push by Big Pharmas to spin off their generics and consumer businesses, Novartis may be on the verge of separating itself from …

Continue Reading →